Target Ranges and PTH Profile in A West African Population Using 2nd and 3rd Generation Tests

C. M. Yao-Yapo *

Laboratory, SAMU CI, Abidjan, Côte d'Ivoire and Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

E. Yayo

Laboratory, SAMU CI, Abidjan, Côte d'Ivoire and Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

K. A. M. Kouacou

Laboratory, SAMU CI, Abidjan, Côte d'Ivoire and Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

J. L. Konan

Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

Y. C. Kouamé-Dia

Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

A. J. Koffi

Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

Y. B. Koné

Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

D. A. Gnionsahié

Hemodialysis Department of Abidjan, Côte d'Ivoire.

M. L. Attoungbré

Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

D. Monnet

Biochemistry Laboratory, Faculty of Pharmacy, University Félix Houphouët Boigny of Abidjan, Côte d'Ivoire BP V34, Abidjan, Côte d'Ivoire.

*Author to whom correspondence should be addressed.


Abstract

Introduction: Bone metabolism disorders are one of the most frequent and serious complications of kidney disease, and are associated with high morbidity and mortality. In order to prevent these bone complications, the Kidney Disease Improving Global Outcomes (KDIGO) expert committee recommends maintaining PTH values within a target range dependent on the race of the population and the generation of test used. The aim of this study was to propose target intervals for monitoring PTH in Ivorian haemodialysis patients according to test generation, and to establish the PTH profile of these patients.

Materials and Methods: This was an analytical cross-sectional study involving 86 black African subjects in apparent good health for the determination of PTH target intervals and 200 black African haemodialysis patients for the PTH profile. Target ranges were determined simultaneously on a 2nd generation Maglumi 800 and 3rd generation kit Vidas (Whole PTH) according to KDIGO (2009) recommendations. The PTH profile of hemodialysis patients was established in comparison with the pre-established target ranges.

Results: The target PTH ranges for dialysis patients were 280.4 to 1261.8 pg/ml for the Maglumi kitÒ and 83.8 to 377.1 pg/ml for the Vidas kitÒ. The mean PTH value in healthy subjects was 21.99 pg/ml, compared with 473.3 pg/ml in haemodialysis patients. According to the target interval established on the VidasÒ kit, 34% of dialysis patients had a PTH value above the upper limit of normality and were therefore at risk of bone complications.

Conclusion: The PTH values of black African Ivorian hemodialysis patients according to the pre-established target intervals were significantly higher in our population than those of Caucasian and Asian populations described in the literature.

Keywords: PTH, West African, target range


How to Cite

Yao-Yapo, C. M., Yayo , E., Kouacou , K. A. M., Konan , J. L., Kouamé-Dia, Y. C., Koffi , A. J., Koné , Y. B., Gnionsahié , D. A., Attoungbré , M. L., & Monnet , D. (2024). Target Ranges and PTH Profile in A West African Population Using 2nd and 3rd Generation Tests. Journal of Advances in Medicine and Medical Research, 36(2), 77–84. https://doi.org/10.9734/jammr/2024/v36i25368

Downloads

Download data is not yet available.

References

Jacquelinet B. Chronic kidney disease. Public health treatise; 2016.

Luo S. et Grams ME. Epidemiology research to foster improvement in chronic kidney disease care. Kidney Int. 2020;97:477–4860.. DOI: 10.1016/j.kint.2019.11.010.

Mineral and bone metabolism disorders in chronic hemodialysis patients in Mauritania: evaluation of adherence to international recommendations (KDOQI and KDIGO), Néphrologie & Thérapeutique. 2017;13(5):333. DOI: 10.1016/j.nephro.2017.08.154

Benabdellah, Karimi I, Bentata Y, Yacoubi H. et Haddiya I. Phospho-calcic status in chronic hemodialysis in Oriental Morocco: Evaluation of adherence to the K/DOQI and KDIGO recommendations, Pan Afr. Med. J. 2013;16.

KDIGO. Clinical Practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2017;7:1–59.

Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone. 2009;44:666–670. DOI: 10.1016/j.bone.2008.12.016

[7] Rodgers SE. et Lew JI. The Parathyroid Hormone Assay. Endocr. Pract. 2011;17:2–6. DOI: 10.4158/EP10297.RA

Yapo A, Assayi MJ, Diaine CH. The reference values of 21 biochemical blood constituents of presumed healthy adult Ivorians, Pharm Afr. 1989;44: 13–24.

Yapo A, Khyssi B, Diomande M, Comoe L, Lonsdorfer A. Determination of the reference values of six biochemical blood constituents of healthy Ivorian adults: preliminary results, Rev Méd Côte Ivoire. 1983;68:14–20.

KDIGO 2009. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD); 2009.

Gannagé-Yared M-H, Kallas-Chémaly M-N, Sleilaty G. Parathormone Levels in a Middle-Eastern Healthy Population Using 2nd and 3rd Generation PTH Assays. Int J Endocrinol; 2020. DOI: 10.1155/2020/6302861

Laradi A, Babinet F, Cremault A, et al., Impact of second generation PTH dosage reference values according to the kit used in the longitudinal follow-up of incident patients (pts) undergoing hemodialysis (HD) from October 2010 to April 2014 at ECHO – Pôle Santé Sud du Mans, Nephrology & Therapeutics. 2014;10(5): 307–308. DOI: 10.1016/j.nephro.2014.07.045

Cavalier E, Salsé M, Dupuy A-M, Bargnoux A-S, Watar F, et al. Establishment of reference values in a healthy population and interpretation of serum PTH concentrations in hemodialyzed patients according to the KDIGO Guidelines using the Lumipulse® G whole PTH (3rd generation) assay, Clin. Biochem. 2018;54: 119–122. DOI: 10.1016/j.clinbiochem.2018.02.019

Cavalier E, Yayo E, Attoungbre-Hauhouot ML, et al., Vitamin D, bone alkaline phosphatase and parathyroid hormone in healthy subjects and haemodialysis patients from West Africa: impact of reference ranges and parathyroid hormone generation assays on the KDIGO guidelines, Clin. Kidney J. 2019;12(2):288–293. DOI: 10.1093/ckj/sfy074.

Migliardi M, Marranca D. Measurement of parathyroid hormone: Variation factors and standardization problems, Immuno-analyse Biol. Specialized. 2006;21(2):119–126. DOI: 10.1016/j.immbio.2005.11.001

Seth J, Sturgeon CM., Ellis AR, Al-Sadie R. UK NEQAS for peptide hormones and related substances, Annu Rev. 1998:A1–4.

Souberbielle JC, Brazier F, Piketty ML, Cormier C, Minisola S, Cavalier E. How the reference values for serum parathyroid hormone concentration are (or should be) established? J. Endocrinol. Invest. 2017;40 (3):241–256. DOI: 10.1007/s40618-016-0553-2

Gannagé-Yared MH, Farès C, Ibrahim T, Rahal ZA, Elias M, Chelala D. Comparison between a second and a third generation parathyroid hormone assay in hemodialysis patients, Metabolism. 2013; 62(10):1416–1422. DOI: 10.1016/j.metabol.2013.05.007

Ljungdahl N, Haarhaus M, Linder C, and Magnusson P. Comparison of 3 Third-Generation Assays for Bio-intact Parathyroid Hormone, Clin. Chem. 2005; 52(5):903–904. DOI: 10.1373/clinchem.2005.065821

Evenepoel P, Jørgensen H, Komaba H, et al., Lower Bone Turnover and Skeletal THA responsiveness in Japanese compared to European patients on hemodialysis, J. Clin. Endocrinol. Metab. 2022;107(12):e4350–e4359. DOI: 10.1210/clinem/dgac522

Chan K, Karaboyas A, Morgenstern H, et al. International and racial differences in mineral and bone disorder markers and treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study, Kidney Med. 2019;1(3):86–96. DOI: 10.1016/j.xkme.2019.04.004

Sawaya BP, Butros R, Naqvi S, Geng Z, et al. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease, Kidney Int. 2003;64(2):737–742. DOI: 10.1046/j.1523-1755.2003.00129.x

Massry SG, Stein R, Garty J. et al. Skeletal resistance to the calcemic action of parathyroid hormone in uremia: Role of 1,25(OH)2D3, Kidney Int. 1976;9(6):467–474. DOI: 10.1038/ki.1976.60.

Rodriguez M, Martin-Malo A, Martinez ME et al. Calcemic response to parathyroid hormone in renal failure: Role of phosphorus and its effect on calcitriol, Kidney Int. 1991;40(6):1055–1062. DOI: 10.1038/ki.1991.314.

Looker A, Dawson-Hughes B, Calvo M, Gunter E, Sahyoun N. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III, Bone. 2002;30(5):771–777. DOI: 10.1016/S8756-3282(02)00692-0

Harris S. and Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women, Am. J. Clin. Nutr. 1998;67 (6):1232–1236. DOI: 10.1093/ajcn/67.6.1232

Cosman F, Morgan D, Nieves J. et al. Resistance to Bone Resorbing Effects of PTH in Black Women, J. Bone Miner. Res. 1997;12(6):958–966. DOI: 10.1359/jbmr.1997.12.6.958

Nelson DA., Vande Vord PJ., Wooley PH. Polymorphism in the vitamin D receptor gene and bone mass in African-American and white mothers and children: A preliminary report, Ann. Rheum. Dis. 2000;59(8):626–630. DOI: 10.1136/ard.59.8.626

Hruska K. New concepts in renal osteodystrophy, Nephrol Dial Transpl. 1998;13:2755–2760.

Monier-Faugere MC, Malluche H. Role of cytokines in renal osteodystrophy, Curr. Opin. Nephrol. Hypertens. 1997;6(4):327–332. DOI: 10.1097/00041552-199707000-00005

Fukagawa M, Yokoyama K, Koiwa F. et al. Clinical practice guideline for the management of chronic kidney disease‐mineral and bone disorder, Ther. Apher. Dial. 2013;17(3):247–288. DOI: 10.1111/1744-9987.12058

Malluche H, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int. Suppl. 1992;38:S62-7. Available:http://www.ncbi.nlm.nih.gov/pubmed/1405383